Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569274 | 0.91 | CYP1A2 (0.68) | CYP1A2KMT2AMEN1MGLLPOLB | |
| SCHEMBL9126383 | 0.87 | CYP1A2 (0.59) | CYP1A2KMT2AMEN1MGLLPOLB | |
| SCHEMBL30063912 | 0.84 | KMT2A (0.66) | CYP1A2KMT2AMEN1POLB | |
| SCHEMBL3983149 | 0.84 | KMT2A (0.66) | CYP1A2KMT2AMEN1POLB | |
| SCHEMBL1568546 | 0.83 | PORCN (0.58) | CNR1CYP1A2KMT2AMEN1MGLL | |
| SCHEMBL31061553 | 0.82 | KMT2A (0.69) | CYP1A2KMT2A | |
| SCHEMBL8065643 | 0.82 | ALDH1A1 (0.70) | CYP1A2KMT2AMEN1POLB | |
| Phenyl 4-Chlorophenylcarbamate SCHEMBL6258165 | 0.82 | ALDH1A1 (0.70) | KMT2AMEN1POLB | |
| SCHEMBL8048626 | 0.82 | CYP1A2 (0.76) | CYP1A2KMT2AMEN1POLB | |
| SCHEMBL30407133 | 0.80 | ALDH1A1 (0.72) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | CNR1 323/4885CYP1A2 3223/4885KMT2A 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.